Zhejiang Aoxiang Pharmaceutical Co., Ltd., headquartered in Taizhou City, Zhejiang Province, was established in 2010 and listed on the Shanghai Stock Exchange in May 2017. We currently have over 1000 employees and multiple subsidiaries both domestically and internationally. The company is planning to establish research and development centers in cities such as Shanghai, Hangzhou, Changsha, and Chengdu. The company is mainly engaged in the research and development, production, and sales of specialty active pharmaceutical ingredients, key intermediates, and pharmaceutical formulations, as well as providing CDMO services to customers. The products are mainly exported to countries and regions such as Europe, the United States, Japan, and South Korea. The company is a national high-tech enterprise and has established platforms such as a national postdoctoral workstation, Zhejiang Province Key Enterprise Research Institute for High end Chiral Drugs, and Zhejiang Province Enterprise Technology Center. At present, the company is actively building a research and development center in Hangzhou. At the end of 2022, Zhejiang Qizheng Pharmaceutical Co., Ltd., a subsidiary of the formulation company located in the main urban area of Taizhou, has started production.
This report is prepared in accordance with relevant national regulations, standards, agreements and technical documents. This unit guarantees the fairness, independence and reliability of the testing work, and is responsible for the tested data; it is not responsible for the consequences caused by partial excerpts or quotations of relevant data in this report
This report is prepared in accordance with relevant national regulations, standards, agreements and technical documents. This unit guarantees the fairness, independence and reliability of the testing work, and is responsible for the tested data; it is not responsible for the consequences caused by partial excerpts or quotations of relevant data in this report
Taizhou Municipal Party Committee, Linhai Municipal party committee leaders visit the company for research